Business Wire

CA-FUJIREBIO/ARIBIO

Share
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration

Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. The agreement provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study launched by AriBio in Dec. 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005122/en/

AriBio completed a Phase 2 study in 2021 in mild to moderate Alzheimer’s disease patients with their lead compound AR1001, a PDE5 inhibitor with preclinical efficacy shown to inhibit neuron apoptosis, promote neurogenesis, increase neuroplasticity, and stimulate autophagy activity to remove toxic proteins. The Phase 3 study in patients with early Alzheimer’s disease, AR1001-ADP3-US01, has been launched in the United States and plans to expand to other countries in 2023.

Fujirebio, a trusted partner for high-quality IVD testing solutions and a pioneer in neurodegenerative disease diagnostics is committed to the advancement of biomarkers to improve diagnosis of Alzheimer’s disease. Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease testing and the first to receive FDA authorization in 2022 for its Lumipulse® G β-Amyloid Ratio (1-42/ 1-40) test. Fujirebio continues to make advances in the field to provide fully automated blood-based tests for Alzheimer’s disease and other neurological disorders.

“AriBio is committed to advancing not just the treatment options for patients with Alzheimer’s disease and their families, but also the development of better diagnostics and improved characterization of this devastating disease. This initial partnership with Fujirebio is the first of several we plan to launch in the next few years as we expand our clinical programs into other areas of neurodegeneration. Fujirebio is an ideal partner for us and reflects our commitment to advancements in this space. We look forward to working closely with Fujirebio to improve the detection of Alzheimer’s disease and other neurodegenerative diseases with their pioneering assays,” commented James Rock, President of AriBio Co., Ltd US Office.

“Fujirebio continues to lead the industry in the development of high quality, functional tests to improve clinicians’ ability to detect and diagnose a variety of neurodegenerative conditions. We continue to partner with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools,” stated Monte Wiltse, President and CEO of Fujirebio Diagnostics, Inc.

About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.

About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.

About Fujirebio
Fujirebio Diagnostics, Inc., a wholly owned subsidiary of H.U. Group Holdings, Inc. and Fujirebio Holdings, Inc., is a premier diagnostics company and the industry leader in cancer biomarker tests. Fujirebio Diagnostics specializes in the contract development and manufacturing for the diagnostics industry leaders and market development of novel in-vitro diagnostic products for the management of human disease states. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at www.fujirebio.com. H.U. Group Holdings, Inc. (formerly known as Miraca Holdings Inc.) is a listed company on the Tokyo Stock Exchange – TYO: 4544.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005122/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global New Material International: Driving a Green Future Through Innovation17.7.2025 04:41:00 CEST | Press release

As global economic integration accelerates, materials science—the foundation of modern industry—is undergoing a profound transformation. Global New Material International Holdings Limited (GNMI) stands at the forefront of this evolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716430383/en/ Colored Building-Integrated Photovoltaic modules developed by CQV, a subsidiary of GNMI. At the recent 2nd Sino-European Corporate ESG Best Practice Conference, GNMI was honored with the “Best Practice in Technological Innovation” award for its outstanding commitment to innovation and green development. The judging panel praised the company’s achievements, noting that “GNMI’s innovations have gained broad international recognition. With a clear strategy focused on green manufacturing and sustainability, the company offers viable solutions to reduce dependence on non-renewable resources while advancing eco-friendly production.” T

Andersen Consulting styrker sin platform med tilføjelsen af Baufest16.7.2025 20:07:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Baufest, et globalt firma inden for digitalt produktdesign og -udvikling. Med mere end 30 års erfaring og kontorer i hele Amerika og Europa er Baufest anerkendt for at kombinere banebrydende teknologi med en dybdegående forståelse af forretningsstrategi og brugeroplevelse. Firmaet tilbyder et omfattende udvalg af tjenester, der omfatter forretningsdesign, udvikling af digitale produkter, data og anvendt AI og cybersikkerhed. Baufest betjener virksomhedskunder på tværs af nøgleindustrier som bank og finans, detailhandel, energi og sundhedspleje med fokus på at skabe målbare forretningsresultater gennem smidig, skalerbar og etisk teknologipraksis. "Vores samarbejde med Andersen Consulting er et vigtigt skridt fremad for de tjenester, vi tilbyder," siger Ángel Pérez Puletti, administrerende direktør for Baufest. "Andersens fulde pakke af specialiserede tjenester bygger på Baufests

ProAmpac Releases 2025 Sustainability Impact Report: A Decade of Flexibility. A Future of Possibilities16.7.2025 18:54:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, announces the release of its 2025 Sustainability Impact Report. This year’s theme, A Decade of Flexibility. A Future of Possibilities. celebrates the company’s decade-long journey of sustainable innovation and sets the foundation for its forward-looking climate and packaging goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716418035/en/ ProAmpac's 2025 Sustainability Impact Report “As we celebrate ten years of growth and innovation, we remain focused on what lies ahead: accelerating circular packaging, lowering our carbon footprint, and creating shared value for our employees, customers, communities, and partners. Our journey is far from over, but with every step, our purpose becomes clearer, and our momentum stronger,” said Greg Tucker, founder, vice-chairman, and chief executive officer of ProAmpac. Key highlights from the 2025 Impact Report incl

EBRD Extends Partnership With HTEC Through New Round of Financing16.7.2025 16:25:00 CEST | Press release

Loan to support company expansion€60 million EBRD financing to support HTEC’s expansionHTEC will use the funds for new acquisitionsThe EBRD continues to foster growth of the technology sector The European Bank for Reconstruction and Development (EBRD) is stepping up support for the Serbian technology industry by backing HTEC, a Serbia-founded AI-first engineering services and digital product development company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716157421/en/ EBRD extends partnership with HTEC through new round of financing. The Bank is providing a €60 million loan to support HTEC’s expansion through strategic acquisitions that will further improve the company’s positioning in key markets. The Bank is providing a €60 million loan to support HTEC’s expansion through strategic acquisitions that will further improve the company’s positioning in key markets. HTEC and the EBRD began their partnership in 2020 with

OpenX Announces OpenXSelect, an Advanced Supply-Side Targeting and Curation Platform for Brands and Agencies16.7.2025 16:05:00 CEST | Press release

OpenXSelect cuts deal setup time by 50% and doubles reach across CTV, native, app, and web. OpenX Technologies, Inc., a leading supply-side platform, today announced the general availability of OpenXSelect™, a next-generation curation and supply-side targeting platform for brands and agencies. Built to bring buyers closer to supply, OpenXSelect enables them to take full control of inventory quality, activate targeting at scale using a wide range of data—including audience, behavioral, attention, and sustainability—and optimize performance through a streamlined, intuitive interface. OpenX has been the leader in supply-side curation since 2018, when it launched OpenAudience™, a first-of-its-kind solution for data partners, powered by the industry’s first supply-side identity graph. OpenAudience set a new standard for activating audiences directly on the supply side and redefined what data-driven curation could look like. OpenXSelect™ builds on that legacy. Developed in close collaboratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye